Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

References

Page 1

	Year	Citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Cancer statistics, 2012 Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal CA A Cancer Journal for Clinicians	2012	10.7K
Signatures of mutational processes in human cancer Nature Somatic VariantTumor HeterogeneityMutational ProcessesCancer GeneticsMedicine	2013	9.9K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie R. Brahmer, Karen L. Reckamp, Paul Baas, New England Journal of Medicine	2015	8.4K
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Nature MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology	2014	5.2K
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Esra A. Akbay, Shohei Koyama, Julián Carretero, Cancer Discovery	2013	1.2K

Page 1